| Dr Midhasso Bulli Foge, PHARMD | |
|
22721 Woodford Tehachapi Rd, Tehachapi, CA 93561-7938 | |
| (763) 439-6526 | |
| Not Available |
| Full Name | Dr Midhasso Bulli Foge |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 22721 Woodford Tehachapi Rd, Tehachapi, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104195510 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 66228 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Midhasso Bulli Foge, PHARMD 22721 Woodford Tehachapi Rd, Tehachapi, CA 93561-7938 Ph: (763) 439-6526 | Dr Midhasso Bulli Foge, PHARMD 22721 Woodford Tehachapi Rd, Tehachapi, CA 93561-7938 Ph: (763) 439-6526 |
News Archive
Marilyn Tavenner has been administrator of Medicare and Medicaid officially for only about a month, but already she faces a policy challenge from Congress. A majority of the House, 145 Republicans and 82 Democrats, wrote to Ms. Tavenner on Wednesday, asking her to delay implementation of a Medicare cost-reduction initiative, scheduled to take full effect July 1, for six months.
"Lawmakers from both parties are telling the White House they will go on vacation next month and leave behind - and incomplete - President Barack Obama's health care overhaul," the Associated Press reports. The White House had long pushed lawmakers to complete their proposal by the recess, a target that now appears unlikely.
CMS officials may have kept the Supreme Court from injecting itself into the controversy over disparate state Medicaid payment rates for various providers through a proposed rule issued Friday.
A team of researchers from Rush University, Yale University, the University of Colorado and the St. Kitts Biomedical Research Foundation transplanted human embryonic stem cells into primate laboratory animals modeled with Parkinson's disease and found "robust survival" of the cells after six weeks and indications that the cells were "well integrated" into the host animals.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.
› Verified 6 days ago
Jessica Beck, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1101 W Tehachapi Blvd, Tehachapi, CA 93561 Phone: 760-784-1011 Fax: 661-826-2502 | |
Dr. Young Yoon Jeon, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 811 Tucker Rd, Tehachapi, CA 93561 Phone: 661-822-9232 | |
Gayane Galayan, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1101 W Tehachapi Blvd, Tehachapi, CA 93561 Phone: 661-823-0163 Fax: 661-823-0742 | |
Minh Nguyen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 710 W Tehachapi Blvd, Tehachapi, CA 93561 Phone: 661-822-3594 | |
Claire Nicole Ferguson, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 775 Tucker Rd, Tehachapi, CA 93561 Phone: 661-823-7094 Fax: 661-823-7096 | |
Dr. Allison Tran-ong, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 811 Tucker Rd, Tehachapi, CA 93561 Phone: 661-822-9232 |